Novartis AG EPS - Earnings per Share 2006-2018 | NVS

Novartis AG annual and quarterly earnings per share history from 2006 to 2018. Earnings per share can be defined as a company's net earnings or losses attributable to common shareholders per diluted share base, which includes all convertible securities and debt, options and warrants.
  • Novartis AG EPS for the quarter ending December 31, 2018 was $0.52, a 38.1% decline year-over-year.
  • Novartis AG EPS for the twelve months ending December 31, 2018 was $5.38, a 65.54% increase year-over-year.
  • Novartis AG 2018 annual EPS was $5.38, a 65.54% increase from 2017.
  • Novartis AG 2017 annual EPS was $3.25, a 16.07% increase from 2016.
  • Novartis AG 2016 annual EPS was $2.8, a 61.59% decline from 2015.
Novartis AG Annual EPS
2018 $5.38
2017 $3.25
2016 $2.80
2015 $7.29
2014 $4.13
2013 $3.70
2012 $3.79
2011 $3.70
2010 $4.26
2009 $3.69
2008 $3.59
2007 $5.13
2006 $3.04
2005 $2.62
Novartis AG Quarterly EPS
Q4 2018 $0.52
Q3 2018 $0.69
Q2 2018 $3.31
Q1 2018 $0.86
Q4 2017 $0.84
Q3 2017 $0.88
Q2 2017 $0.83
Q1 2017 $0.70
Q4 2016 $0.40
Q3 2016 $0.81
Q2 2016 $0.75
Q1 2016 $0.84
Q4 2015 $0.45
Q3 2015 $0.77
Q2 2015 $0.75
Q1 2015 $5.32
Q4 2014 $0.60
Q3 2014 $1.31
Q2 2014 $1.03
Q1 2014 $1.19
Q4 2013 $0.82
Q3 2013 $0.90
Q2 2013 $1.01
Q1 2013 $0.97
Q4 2012 $0.80
Q3 2012 $0.98
Q2 2012 $1.09
Q1 2012 $0.92
Q4 2011 $0.38
Q3 2011 $1.01
Q2 2011 $1.11
Q1 2011 $1.20
Q4 2010 $0.94
Q3 2010 $0.99
Q2 2010 $1.05
Q1 2010 $1.28
Q4 2009 $1.02
Q3 2009 $0.92
Q2 2009 $0.89
Q1 2009 $0.86
Q4 2008 $0.67
Q3 2008 $0.92
Q2 2008 $0.98
Q1 2008 $1.02
Q4 2007 $0.40
Q3 2007 $2.96
Q2 2007 $0.85
Q1 2007 $0.92
Q4 2006 $0.70
Q3 2006 $0.79
Q2 2006 $0.72
Q1 2006 $0.83
Q4 2005 $0.58
Q3 2005 $0.71
Q2 2005 $0.70
Q1 2005 $0.63
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $176.507B $51.900B
Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders - their customers, their people, their shareholders and the communities in which they live and work.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $368.953B 16.73
Pfizer (PFE) United States $234.424B 13.13
Merck (MRK) United States $197.334B 16.86
Eli Lilly (LLY) United States $119.326B 20.72
Novo Nordisk (NVO) Denmark $118.242B 19.13
AbbVie (ABBV) United States $114.422B 9.81
Sanofi (SNY) France $103.609B 12.79
GlaxoSmithKline (GSK) United Kingdom $98.852B 12.98
AstraZeneca (AZN) United Kingdom $98.276B 11.21
Bristol-Myers Squibb (BMY) United States $74.378B 11.44